<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T04:51:39Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/19889" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/19889</identifier><datestamp>2026-10-18T21:11:54Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Robot-assisted laparoscopic radical prostatectomy: A single center initial experience</dc:title><dc:creator>karabulut, ibrahim</dc:creator><dc:creator>YILMAZEL, Fatih Kürşat</dc:creator><dc:creator>YILMAZ, Ali Haydar</dc:creator><dc:creator>keskin, ercüment</dc:creator><dc:subject>Genel ve Dahili Tıp</dc:subject><dc:subject>Cerrahi</dc:subject><dc:description>Aim: The aim of this study is to present the surgical, oncologic and functional results of the first 34 robotic radical prostatectomy(RARP) procedures performed in our clinic.Material and Methods: Data of 34 patients who underwent RARP between July 2017 and October 2019 were evaluated.Results: The mean patient age was 58.73±4.94 years, and the mean preoperative serum prostate-specific antigen level was 8.9±2.07ng/mL. Bilateral neurovascular bundle (NVB) sparing, unilateral NVB-sparing, and non-NVB-sparing surgery were performed in7.5, and 22 cases, respectively. The mean prostate weight was 58.73±26.03g. Anterior reconstruction suture was performed in 22(64.7%) cases. Mean console time, intraoperative blood loss, duration of hospital stay, and urethral catheter removal time were195.2±14.03min, 120.3±21.2cc, 7.34±1.62 days, and 7.26±1.26 days, respectively. Biochemi¬cal recurrence was observed in twopatients, one of whom received maximal androgen blockage (MAB), and the other one received pelvic radiotherapy+MAB. All thepatients with at least one-year follow-up were fully continent (0 pads/day). Of the 16 (47%) patients with no preoperative erectiledysfunction (ED) and with at least three-month follow-up, 9 (62.5%) had no ED, with or without any additional medica¬tion includingphosphodiesterase-5 (PDE5) inhibitors.Conclusion: RARP is a safe minimally invasive procedure with acceptable morbidity, excellent operative, pathological and oncologicaloutcomes, and satisfactory functional results.</dc:description><dc:date>2019</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/19889</dc:identifier><dc:identifier>https://doi.org/10.5455/annalsmedres.2019.11.760</dc:identifier><dc:language>en</dc:language><dc:relation>Annals of Medical Research</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/19889</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>